|
    MRNA U.S.: Nasdaq

    Moderna Inc.

    MRNAUS
    After Hours
    Last Updated: Sep 24, 2021 7:59 p.m. EDT Delayed quote

    $ 433.00

    2.86 0.66%
    After Hours Volume: 106.91K
    Close Chg Chg %
    $430.14 -24.46 -5.38%
    Advanced Charting
    Volume: 12.98M 65 Day Avg: 18.18M
    71% vs Avg
    426.61 Day Range 453.61
    65.49 52 Week Range 497.49

    Your Watchlists

    Customize eLesor

    Have Watchlists? Log in to see them here or sign up to get started.

    Symbol
    Company
    Price
    Chg/Chg %
    No Items in Watchlist

    There are currently no items in this Watchlist.

    Uh oh

    Something went wrong while loading Watchlist.

    Recently Viewed Tickers

    No Recent Tickers

    Visit a quote page and your recently viewed tickers will be displayed here.

    MRNA Overview

    Performance

    5 Day
    • 0.02%
    1 Month
    • 12.54%
    3 Month
    • 95.57%
    YTD
    • 311.74%
    1 Year
    • 519.17%

    Analyst Ratings

    • Sell
    • Under
    • Hold
    • Over
    • Buy
    Number of Ratings 16 Full Ratings

    Recent News

    Read full story

    Moderna Inc. stock underperforms Friday when compared to competitors

    CDC: We are not changing the definition of 'fully vaccinated' now that COVID-19 boosters are available

    Moderna to Supply Covid-19 Vaccine Doses in Peru

    Read full story

    Pfizer Vaccine Boosters Officially Approved. What to Know.

    Read full story

    Whether COVID-19 boosters get approved or not, Pfizer and Moderna have already made their money

    Read full story

    Moderna Inc. stock rises Thursday, outperforms market

    Read full story

    FDA Authorizes Pfizer Booster for Some Americans. The CDC’s Call on the Rollout Could Come Today.

    Read full story

    Moderna Inc. stock outperforms market on strong trading day

    Read full story

    Global tally of COVID-19 cases nears 230 million, as Biden convenes virtual pandemic summit and doubles U.S. purchase of Pfizer vaccine

    Read full story

    CDC Committee Will Consider Pfizer Booster. What to Know.

    Read full story

    This Fund Is Winning Big by Betting on Stocks That Help Humanity

    Read full story

    Moderna Inc. stock outperforms competitors on strong trading day

    Read full story

    J&J Says Its Booster Shot Works, but Its Vaccine Remains Effective Without a Second Dose

    Read full story

    Moderna Inc. stock outperforms market despite losses on the day

    Read full story

    Upbeat result of COVID-19 vaccine trial in 5- to 11-year-olds tempered as U.S. daily death rate tops 2,000 for first time since March 1

    Read full story

    FDA Panel Is a Win for Pfizer, Despite Mixed Result, Analyst Says

    Read full story

    FDA panel recommends Pfizer’s COVID-19 booster for 65 and older, but not for the general public

    Read full story

    It’s Crunchtime for Evergrande. The Market Is Worried.

    Read full story

    WHO warns lack of COVID-19 vaccine supply in Africa could make it breeding ground for new variants and ‘send the whole world back to square one’

    Read full story

    FDA Committee Vote Is a Rebuff to Biden. Impact on Vaccine Makers Is Less Clear.

    5 Top Dividend Kings to Buy Now and Hold Forever

    on Motley Fool

    Is Novavax Delaying Its COVID Vaccine EUA Filings Yet Again?

    on Motley Fool

    Is It Too Late to Buy Moderna Stock?

    on Motley Fool

    Moderna Inc (MRNA) CEO Stephane Bancel Sold $8.3 million of Shares

    on GuruFocus.com

    7 Companies Set to IPO That Could Be the Next Big Thing

    on InvestorPlace.com

    AstraZeneca (AZN) Inks Deal to Enter Novel RNA Therapeutic Space

    on Zacks.com

    Novavax (NVAX) Applies to WHO for COVID-19 Vaccine Listing

    on Zacks.com

    Where to Invest $10,000 in a Bear Market

    on Motley Fool

    Pfizer (PFE) Booster Dose Gets CDC Backing for Older Adults Only

    on Zacks.com

    3 Things You Shouldn't Do if the Stock Market Crashes

    on Motley Fool

    Why Are Top Scientists Opposing COVID Boosters?

    on Motley Fool

    Novavax Is a Short-Term Trade in a Long-Term Paradigm

    on InvestorPlace.com

    Will Pfizer ETFs Soar on FDA's COVID-19 Vaccine Booster Approval?

    on Zacks.com

    Why BioNTech Thrashed the Market on Thursday

    on Motley Fool

    10 Oversold Stocks to Buy for the Final Quarter

    on InvestorPlace.com

    Dynavax (DVAX) Gains on Clover's COVID-19 Vaccine Study Data

    on Zacks.com

    Pfizer (PFE) Booster Dose Gets FDA Nod for High-Risk People

    on Zacks.com

    4 Top Biotech Stocks to Watch as Economic Recovery Picks Up Pace

    on Zacks.com

    The Zacks Analyst Blog Highlights: Moderna, Quanta Services, Avantor, ON Semiconductor and KLA

    on Zacks.com

    Should You Invest in the Invesco DWA Healthcare Momentum ETF (PTH)?

    on Zacks.com

    Moderna Inc.

    Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

    Competitors

    Name Chg % Market Cap
    Johnson & Johnson -0.30% $432.67B
    Pfizer Inc. -0.57% $246.36B
    AstraZeneca PLC 2.04% £137.02B
    AstraZeneca PLC ADR 1.53% $187.38B
    BioNTech SE ADR -5.53% $80.87B
    GlaxoSmithKline PLC -1.84% £64.54B
    Gilead Sciences Inc. -0.70% $89.26B
    Regeneron Pharmaceuticals Inc. -1.18% $68.33B
    Biogen Inc. -0.51% $43.47B
    CureVac N.V. 0.33% $10.81B
    Competitor Data Provided ByCapital Cube Logo